7-(bromomethyl)benzofuran | 95333-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 7-(bromomethyl)benzofuran
• 英文别名: 7-(bromomethyl)-1-benzofuran
• CAS: 95333-19-0
• 化学式: C₉H₇BrO
• 分子量: 211.058
• InChiKey: SBEAPOAYRQDHJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  263.5±15.0 °C(Predicted)
• 密度：
  1.553±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-(bromomethyl)benzofuran 在 乌洛托品 作用下， 以70%的产率得到苯并[b]呋喃-7-甲醛
  参考文献：
  名称：

  有机羰基化合物的构象分析。第4部分。苯并[ b ]呋喃的甲酰基和乙酰基衍生物的1 H和13 C核磁共振研究

  摘要：

  苯并[ b ]呋喃的甲酰基和乙酰基衍生物的构象研究提供了证据，表明在2和7衍生物的情况下，E，Z-构象混合物是溶剂依赖性的，Z-形式在极性较高的溶剂中占主导地位。在3-位和4-位上存在相同的取代基可得到主要具有Z-构象的化合物，并且不会因溶剂引起变化。这些结果表明，相对于相同的苯并[ b ]噻吩衍生物，苯并[ b ]呋喃的羰基衍生物具有令人感兴趣的不同行为。构象分析是通过nmr方法采用1 H和13 C化学位移，远距离质子-质子耦合常数和镧系元素诱导的位移（LIS）模拟。对于在7位取代的衍生物，LIS方法不适用于确定构象异构体，因为在溶液中会形成螯合物，其中Eu与羰基和杂环的氧原子键合以稳定Z -形式。通过对远距离质子-质子耦合常数，质子化学位移和经典介电理论的统计处理，建立了确定苯并[ b ]呋喃-7-甲醛的相对构象种群的定量方法。

  DOI：

  10.1039/p29840001479
• 作为产物：
  描述：

  methyl benzofuran-7-carboxylate 在 lithium aluminium tetrahydride 、 甲基磺酰氯 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 7-(bromomethyl)benzofuran
  参考文献：
  名称：

  [EN] ANTIBACTERIAL COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS ANTIBACTÉRIENS ET UTILISATIONS DE CEUX-CI

  摘要：

  本发明涉及式(I)的化合物，包括其任何立体化异构体或其药学上可接受的盐，用于治疗结核病。

  公开号：

  WO2017155909A1

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。
• Antibacterial compounds and uses thereof
  申请人：The Global Alliance for TB Drug Development, Inc.

  公开号：US10508097B2

  公开（公告）日：2019-12-17

  The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

  本发明涉及用于治疗结核病的式 (I) 化合物，包括其任何立体化学异构体形式，或其药学上可接受的盐类。
• 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
  作者：Hamish S. Sutherland、Amy S.T. Tong、Peter J. Choi、Adrian Blaser、Daniel Conole、Scott G. Franzblau、Manisha U. Lotlikar、Christopher B. Cooper、Anna M. Upton、William A. Denny、Brian D. Palmer

  DOI：10.1016/j.bmc.2019.02.026

  日期：2019.4

  Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drugresistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG. Bedaquiline is highly lipophilic and has an extremely long terminal half-life, so has the potential for more-than-desired accumulation in tissues during the relatively long treatment durations required to cure TB. The present work is part of a program that seeks to identify a diarylquinoline that is as potent as bedaquiline against Mycobacterium tuberculosis, with lower lipophilicity, higher clearance, and lower risk for QT prolongation. Previous work led to the identification of compounds with greatly-reduced lipophilicity compounds that retain good anti-tubercular activity in vitro and in mouse models of TB, but has not addressed the hERG blockade. We now present compounds where the C-unit naphthalene is replaced by a 3,5dialkoxy- 4-pyridyl, demonstrate more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. Two examples of this series are in preclinical development.
• BENASSI, R.;FOLLI, U.;LAROSSI, D.;SCHANETTI, L.;TADDEI, F., J. CHEM. SOC. PERKIN TRANS., 1984, N 9, 1479-1485
  作者：BENASSI, R.、FOLLI, U.、LAROSSI, D.、SCHANETTI, L.、TADDEI, F.

  DOI：——

  日期：——